Voyager Therapeutics (VYGR) FCF Margin (2015 - 2026)
Voyager Therapeutics (VYGR) posted FCF Margin of 1289.36% for Q1 2026, down 590.2% sequentially from 186.81% in Q4 2025, and down 69376.0% YoY from N/an in Q1 2025.
Voyager Therapeutics (VYGR) FCF Margin (2015 - 2026) Analysis & Trends
Voyager Therapeutics has reported FCF Margin for 12 years, with the latest figure at 1289.36% in Q1 2026.
- Quarterly FCF Margin fell 69376.0% year-over-year to 1289.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 349.76% (down 17637.0% YoY) and the FY2025 annual result came in at 329.16%, down 30562.0% from the prior year.
- FCF Margin fell to 1289.36% in Q1 2026 per VYGR's latest filing, from 186.81% in the prior quarter.
- Over five years, FCF Margin peaked at 5197.26% in Q1 2022 and troughed at 2580.06% in Q2 2022.
- A 5-year average of 9.89% and a median of 117.23% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin jumped 553058 bps in 2022, then sank 511549 bps in 2023.
- Over 5 years, FCF Margin stood at 850.13% in 2022, then plunged by 103 bps to 27.21% in 2023, then sank by 757 bps to 233.04% in 2024, then grew by 20 bps to 186.81% in 2025, then tumbled by 590 bps to 1289.36% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 1289.36%, 186.81%, and 233.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | -813.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -813.81% |
| Mar 31, 2026 | -1,289.36% |
| Dec 31, 2025 | -186.81% |
| Sep 30, 2025 | -233.86% |
| Jun 30, 2025 | -660.88% |
| Mar 31, 2025 | -595.60% |
| Dec 31, 2024 | -233.04% |
| Sep 30, 2024 | -114.60% |
| Jun 30, 2024 | -117.23% |
| Mar 31, 2024 | 301.29% |
| Dec 31, 2023 | -27.21% |
| Sep 30, 2023 | -509.32% |
| Jun 30, 2023 | -7.71% |
| Mar 31, 2023 | 81.78% |
| Dec 31, 2022 | 850.13% |
| Sep 30, 2022 | -42.96% |
| Jun 30, 2022 | -2,580.06% |
| Mar 31, 2022 | 5,197.26% |
| Dec 31, 2021 | 39.35% |
| Sep 30, 2021 | -1,352.09% |